On November 9, 2020 Seagen Inc. (Nasdaq:SGEN) reported the presentation of immuno-oncology data from its broad pipeline of therapies at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s (SITC) (Free SITC Whitepaper) 35th Anniversary Annual Meeting 2020, taking place virtually November 9-14, 2020 (Press release, Seagen, NOV 9, 2020, View Source [SID1234570310]). Six abstracts will highlight the company’s continued progress in advancing innovative research for marketed and late-stage antibody-drug conjugates (ADCs) and innovative empowered antibody pipeline utilizing its proprietary sugar-engineering antibody (SEA) technology.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Data presented at SITC (Free SITC Whitepaper) will demonstrate how Seagen’s monomethyl auristatin E (MMAE)-based ADCs induce immunogenic cell death (ICD) by activating the innate immune cells and changing the tumor microenvironment to a more inflammatory state thereby enhancing the efficacy of other cancer immunotherapies. These findings will be presented for tisotumab vedotin, ladiratuzumab vedotin and across vedotin-based ADCs (Abstracts #617, #618 and #323).

"Our vedotin-based ADC research at SITC (Free SITC Whitepaper) illustrates the impact of immunogenic cell death on the tumor microenvironment," said Roger Dansey, M.D., Chief Medical Officer at Seagen. "Importantly, these data support the mechanistic rationale for combining vedotin-based ADCs with immuno-oncology therapies in the clinic."

Data will also be presented utilizing Seagen’s proprietary SEA technology, which produces nonfucosylated antibodies that uniquely enhance activity targeting key immune modulating receptors. Preclinical data will be presented from SEA-TGT (Abstract #250), a novel investigational nonfucosylated human IgG1 TIGIT antibody. SEA-TGT is in an ongoing phase 1 clinical trial for patients with solid tumors and lymphoma (NCT04254107). In addition, preclinical data will be presented for SEA-CD40 (Abstract #438), a novel investigational, nonfucosylated human IgG1 antibody targeted to CD40, an immune stimulatory receptor found on antigen-presenting cells. SEA-CD40 is in a phase 1 trial for pancreatic cancer in combination with chemotherapy and a PD-1 inhibitor (NCT02376699).

"We believe our immuno-oncology candidates have a best-in-class potential, creating a strong foundation for our immunotherapy pipeline," said Scott Peterson, Ph.D., Senior Vice President of Research at Seagen. "Data presented at SITC (Free SITC Whitepaper) demonstrate that our sugar-engineered antibodies are differentiated and have the potential to improve efficacy and address unmet needs in cancer."

Data regarding ADCETRIS (brentuximab vedotin) will be presented demonstrating its ability to selectively target and kill CD30-positive T regulatory cells (Tregs) that contribute to resistance to cancer immunotherapies (Abstract #696). These data support that ADCETRIS may have an immunomodulatory effect through selective depletion of highly active Tregs.

The abstracts published in advance of the SITC (Free SITC Whitepaper) Annual Meeting can be found here. All data presentations will be available on-demand starting on November 11, 2020.

Details of Seagen Presentations at SITC (Free SITC Whitepaper) Annual Meeting 2020:

Abstract Title

Abstract No.

Presentation

Type / Date

Presenter

Brentuximab vedotin, a CD30 targeting antibody-drug conjugate, selectively depletes activated Tregs in vitro and in vivo

#696

E-Poster /

November 11-14

B. Grogan

Tisotumab vedotin shows immunomodulatory activity through induction of immunogenic cell death

#617

E-Poster /

November 11-14

E. Gray

Systemic administration of ladiratuzumab vedotin alone or in combination with pembrolizumab results in significant immune activation in the tumor microenvironment in metastatic breast cancer patients

#323

E-Poster /

November 11-14

L. Pusztai

Synergy between SEA-CD40 and chemotherapeutics drives curative anti-tumor activity in pre-clinical models

#438

E-Poster /

November 11-14

W. Zeng

SEA-TGT is a nonfucosylated antibody with distinct and amplified effector function activity that leverages the dependencies of anti-TIGIT anti-tumor activity upon FcγR engagement

#250

E-Poster /

November 11-14

A. Smith

Vedotin ADCs induce ER stress and elicit hallmarks of ICD across multiple cancer indications

#618

E-Poster /

November 11-14

K. Klussman